|NASDAQ: AKYA||Healthcare / Medical Devices & Instruments / USA|
|7.88||+0.1900||+2.47%||Vol 91.35K||1Y Perf -32.43%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||18.00||Analyst Rating||Strong Buy 1.07|
|Potential %||128.43||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/43||Value Ranking||★ 40.49|
|Insiders Value % 3/6/12 mo.||-100/-100/41||Growth Ranking||★ 36.46|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/39||Income Ranking||— -|
|Price Range Ratio 52W %||7.26||Earnings Rating||—|
|Market Cap||302.13M||Earnings Date||4th May 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Q01 2021||-0.15||-2.85||-1 800.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2023|
|Estimated EPS Next Report||-0.46|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||264.31K|
|Avg. Monthly Volume||144.11K|
|Avg. Quarterly Volume||117.62K|
Akoya BioSciences Inc. (NASDAQ: AKYA) stock closed at 7.88 per share at the end of the most recent trading day (a 2.47% change compared to the prior day closing price) with a volume of 91.35K shares and market capitalization of 302.13M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 169 people. Akoya BioSciences Inc. CEO is Brian McKelligon.
The one-year performance of Akoya BioSciences Inc. stock is -32.43%, while year-to-date (YTD) performance is -17.66%. AKYA stock has a five-year performance of %. Its 52-week range is between 7.2 and 16.57, which gives AKYA stock a 52-week price range ratio of 7.26%
Akoya BioSciences Inc. currently has a PE ratio of -5.30, a price-to-book (PB) ratio of 5.02, a price-to-sale (PS) ratio of 6.81, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.19%, a ROC of -43.08% and a ROE of -65.08%. The company’s profit margin is -96.51%, its EBITDA margin is -84.90%, and its revenue ttm is $53.64 Million , which makes it $1.41 revenue per share.
Of the last four earnings reports from Akoya BioSciences Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Akoya BioSciences Inc.’s next earnings report date is 04th May 2023.
The consensus rating of Wall Street analysts for Akoya BioSciences Inc. is Strong Buy (1.07), with a target price of $18, which is +128.43% compared to the current price. The earnings rating for Akoya BioSciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Akoya BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Akoya BioSciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 52.41, ATR14 : 0.71, CCI20 : -91.57, Chaikin Money Flow : -0.05, MACD : -1.00, Money Flow Index : 8.08, ROC : -25.80, RSI : 29.89, STOCH (14,3) : 16.55, STOCH RSI : 0.96, UO : 41.78, Williams %R : -83.46), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Akoya BioSciences Inc. in the last 12-months were: Brian McKelligon (Option Excercise at a value of $10 605), Brian McKelligon (Sold 35 000 shares of value $397 542 ), Garry Nolan (Sold 63 106 shares of value $839 235 ), Joseph Driscoll (Option Excercise at a value of $120 830), Joseph Driscoll (Sold 24 613 shares of value $308 706 ), Niro Ramachandran (Option Excercise at a value of $99 287), Thomas P. Schnettler (Sold 71 050 shares of value $925 782 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
CEO: Brian McKelligon
Telephone: +1 855 896-8401
Address: 100 Campus Drive, 6th Floor, Marlborough 01752, MA, US
Number of employees: 169
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.